Biogen Idec (BIIB): Price to Earnings Adjusted for Growth Rate
Biogen Inc. combines strict environmental responsibility with premium pricing for exclusive drugs treating rare pathologies. The balanced price-to-earnings to growth ratio on the GURU.Markets terminal chart reflects current dynamics, where 2.48 expresses today's metric value. The business is currently undergoing a portfolio refresh, anticipating the commercial success of new medications to overcome a cyclical downturn.
Biogen Inc. (BIIB) - metric breakdowns and financial figures
- price and consensus price forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- earnings and market multiples details:
BIIB - Net Income|Company Profit Forecast Biogen Inc.|BIIB - P/E Multiple|Future Price to Earnings Biogen Idec|BIIB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Biogen Corp|BIIB - Operating profit EBITDA|Net earnings per share for the last four quarters Biogen|BIIB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months biogen.com|BIIB - Earnings per share growth in current year|Projected earnings per share growth rate for next year Biogen Inc.
General company analysis:BIIB, Biogen Inc
High promotion costs for new Alzheimer's treatments, coupled with the stagnation of legacy products, are limiting the current margins of Biogen Inc. (BIIB). This under-valuation indicator relative to growth compares the P/E multiple with earnings growth rates, determining whether the business expansion dynamics justify the current market value of the shares or if the asset is trading at a discount to its potential.
Competitors of Biogen Inc.
Growth-Adjusted Market Cap to Net Income Neurocrine|Price/Earnings to Growth Ratio Regencell RGC|Axsome Corp (AXSM) - Price to Earnings Adjusted for Growth Rate|ACADIA Pharmaceuticals - PEG Multiple|Price to Net Income Growth Ratio xenon-pharma.com (XENE)|VKTX: PEG Multiple|Price to Earnings Adjusted for Growth Rate Supernus Pharmaceuticals, Inc. (SUPN)|Price/Earnings to Growth Ratio Catalyst Pharmaceuticals Inc|Growth-Adjusted P/E Ratio DNLI (Denali Corp)|Price/Earnings to Growth Multiple HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - Growth-Adjusted Payback Ratio|PEG Multiple AMLX (Amylyx Pharmaceuticals, Inc.)|Growth-Adjusted Market Cap to Net Income Trevi Therapeutics Inc (TRVI)|PRAX - Price/Earnings to Growth Ratio|AVXL (Anavex Life Sciences Corp) - Growth-Adjusted P/E Ratio|CBLL: PEG Multiple|Price/Earnings to Growth Multiple Prothena|Price/Earnings to Growth Multiple ALEC|Annexon Biosciences (ANNX) - Growth-Adjusted Market Cap to Net Income|PEG Multiple OMER|Price/Earnings to Growth Ratio NGNE (Neurogene Therapeutics)|PEG Multiple ACIU (AC Immune)|Growth-Adjusted Market Cap to Net Income voyagertherapeutics.com (VYGR)|Neumora Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income Scilex Holding SCLX|TVGN: PEG Multiple|ACOG (Alpha Cognition Inc.) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Cognition Therapeutics|Growth-Adjusted P/E Ratio IKT (inhibikase.com)|PEG Multiple SAVA|ASRT - Price to Earnings Adjusted for Growth Rate|Coya Therapeutics - Price/Earnings to Growth Multiple|PEG Multiple VistaGen Therapeutics, Inc. VTGN|OVID - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ABOS (acumenpharm.com)|CervoMed (CRVO) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Alterity Therapeutics Limited (ATHE)|CLNN (Clene Inc) - PEG Multiple|Price/Earnings to Growth Ratio PEPG|PEG Multiple JUNS|Growth-Adjusted Market Cap to Net Income relmada.com|Price/Earnings to Growth Ratio Annovis Bio ANVS|Grace Therapeutics Inc (GRCE) - Price to Earnings Adjusted for Growth Rate|Firefly Neuroscience Inc - PEG Multiple|Price to Net Income Growth Ratio Klotho Neurosciences Inc (KLTO)|NRSN: PEG Multiple|Price to Earnings Adjusted for Growth Rate revivapharma.com (RVPH)|Price/Earnings to Growth Ratio MetaVia Inc.|Growth-Adjusted P/E Ratio NRXS (NeurAxis Inc.)|Price/Earnings to Growth Multiple HSDT (Helius Medical)|PASG (passagebio.com) - Growth-Adjusted Payback Ratio|PEG Multiple NEUP (Neuphoria Therapeutics)|Growth-Adjusted Market Cap to Net Income minervaneurosciences.com (NERV)|ATHA - Price/Earnings to Growth Ratio|ADXN (Addex Therapeutics Ltd.) - Growth-Adjusted P/E Ratio|ALZN: PEG Multiple|Price/Earnings to Growth Multiple Cyclerion Therapeutics, Inc.|Price/Earnings to Growth Multiple PTIX|Pasithea (KTTA) - Growth-Adjusted Market Cap to Net Income|PEG Multiple CRGT|Price/Earnings to Growth Ratio ATXI (Avenue Therapeutics Inc.)|PEG Multiple BCLI (Brainstorm Cell Therapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Cara Therapeutics Inc (CARA)|Chromocell Therapeutics - PEG Multiple|Growth-Adjusted Market Cap to Net Income Eliem Therapeutics ELYM|ITCI: PEG Multiple|LBPH (Longboard Pharmaceuticals Inc) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Marinus|Growth-Adjusted P/E Ratio NKGN (NKGen Biotech Corp)|PEG Multiple NRBO|SAGE - Price to Earnings Adjusted for Growth Rate|Synaptogenix - Price/Earnings to Growth Multiple|PEG Multiple Trevena Inc. TRVN|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical Inc.)|Cerevel Therapeutics (CERE) - Price/Earnings to Growth Ratio
